Connect with us

Business

Generation Lab raises $11 million, becoming Accel’s first longevity bet

Published

on



The word “longevity” derives from Latin, and more or less means “long life” or “great age.”

Each translation is informative at a time when people are simultaneously living longer than ever, and gathering increasingly personalized health data through wearables, devices, and tests. Longevity has become a banner industry in recent years, bolstered by the expansive cultural influence of entrepreneur Bryan Johnson and his famous slogan, “Don’t Die.” 

Now, we’re all slated to die at some point. However, there’s a salient question and pursuit at the center of the longevity boom—if we’re living longer lives, what does it mean to live out those years fully? If we monitor our health thoughtfully throughout our lives, can we have more years that are high-quality, active, and independent? It’s a question that Generation Lab, a startup providing personalized epigenetic testing, seeks to answer. 

“We’re aiming to add 20 extra healthy years to your life—more years where you can play tennis, run around, travel,” said Alina Su, Generation Lab cofounder and CEO. “We’re not talking about living forever, we’re talking about living healthier for a longer time.” 

Generation Lab—started in 2023 by Su, Berkeley’s Dr. Irina Conboy, and Michael Suswal—is so named because the cofounding team spans three generations: Conboy—regarded as the “mother of longevity” for her decades of cell regeneration work—is a Baby Boomer, while Suswal is a millennial whose previous company was unicorn Standard AI. Su, Gen Z and effusive, chased down Conboy while an undergraduate at Berkeley. The three believe we’re on the cusp of an “ageless generation,” where people will be defined by their ability to be active for longer periods and linger around a “biological 30.” 

If this seems a touch far-fetched, consider: Generation Lab is now Accel’s first bet in the longevity space. The Silicon Valley stalwart has led Generation Lab’s $11 million seed round, Fortune has exclusively learned. Samsung Next also participated, plus an array of celebrity investors including Steve Aoki’s Aoki Labs, Giannis Antetokounmpo’s BYL Ventures, and Simu Liu’s Markham Valley Ventures. This round brings the company’s total funding so far to $15 million.

“Longevity’s going to be one of the biggest markets of our generation,” said Accel partner Kerry Wang, adding that: “As people start spending more money on [longevity] treatments, they’re not just spending it on things that don’t matter… there needs to be a trusted eval for longevity.”

Generation Lab’s product is its SystemAge report, which starts with a blood draw. The blood test analyzes 460 different biomarkers across 19 organs and systems, then provides a detailed breakdown of how quickly each part of your body is aging. (I took the test myself—thrilled to report my cardiac and auditory systems are aging in reverse, while my blood and vascular system needs some work.) The goal: Pinpointing health signals and potential problems before symptoms appear. Right now, the test is rolled out as an option for more than 300 clinic partners in 18 countries, Kim Kardashian’s doctor among them. The test costs $490, with additional options for subscription-based testing.

That’s cost-prohibitive for most, but Suswal has been thinking about societal downstream possibilities for Generation Lab’s tests, especially in relation to public health: “Imagine if everyone in the country took the test, we could have predicted issues like the Flint Water Crisis.”

Conboy pointed out something to me that I’ve been pondering since we met: Much in the same way we all experience time differently, aging also isn’t linear: It happens in fits and starts, plateaus and accelerations. (No one, for example, grows exactly one grey hair each day.) Aging also continuously evolves around technological and societal advancement. 

“See, on a long enough timescale, everyone’s survival rate becomes zero,” Conboy laughs. “The question is, how long is the timeline?… The directional goal of longevity in academia—or in a company—is to expand [quality of life in our final years]. Remember, 100 years ago, 40 years of age was very old, people died then. Then, we invented antibiotics, sanitation, and then vaccines. And now we move on to the next breakthrough.”

See you tomorrow,

Allie Garfinkle
X:
@agarfinks
Email: alexandra.garfinkle@fortune.com
Submit a deal for the Term Sheet newsletter here.

Joey Abrams curated the deals section of today’s newsletter. Subscribe here.

Venture Deals

Findem, a Redwood City, Calif.-based AI-powered hiring platform, raised $51 million in funding. SLW led the round and was joined by Wing Ventures and others.

ROLLER, an Austin, Texas-based venue management platform, raised $50 million in funding. Insight Partners led the round and was joined by J.P. Morgan.

Starbridge.ai, a New York City-based AI-powered sales platform designed for the public sector, raised $42 million in Series A funding. Craft Ventures led the round and was joined by others.

Pave Bank, a Singapore and Tbilisi, Georgia-based commercial bank designed for integration with digital assets, raised $39 million in funding. Accel led the round and was joined by Tether Investments, Quona Capital, Wintermute, Helios Digital Ventures, and others.

Sumble, a San Francisco-based sales intelligence platform, raised $38.5 million across seed and Series A rounds led by Canaan Partners and Coatue, joined by Square Peg Capital, Zetta Venture Partners, Bloomberg Beta, and others.

CurbWaste, a New York City-based operating system for waste hauling, raised $28 million in Series B funding. Socium Ventures led the round and was joined by Flourish Ventures, TTV Capital, B Capital Group, and SquarePoint Capital.

VitriVax, a Boulder, Colo.-based vaccine formulation technology company, raised $17.3 million in Series B funding. Adjuvant Capital and RA Capital Management led the round.

SenseNet, a North Vancouver, Canada-based developer of wildfire detection platform, raised $14 million in Series A funding. Stormbreaker led the round and was joined by Thin Line Capital, Fusion Fund, Plaza Ventures, FOLD36 Capital, and B Current Impact Investment.

Gimlet Labs, a San Francisco-based applied AI research and product company, raised $12 million in seed funding. Factory led the round and was joined by angel investors.

roclub, a Berlin, Germany-based teleoperation platform for medical technology, raised $11.7 million in Series A funding. Smedvig Ventures and YZR led the round and were joined by Speedinvest and angel investors.

Acoru, a Madrid, Spain-based fraud detection platform, raised €10 million ($11.6 million) in Series A funding. 33N Ventures led the round and was joined by Adara Ventures and Athos Capital.

Casium, a Seattle, Wash.-based platform designed to accelerate and simplify immigration processes, raised $5 million in seed funding. Maverick Ventures led the round and was joined by A12 Incubator, GTfund, Success Venture Partners

Coolant, a San Francisco-based company using 3D vision and AI for environmental intelligence, raised $4.3 million across seed and pre-seed rounds. General Catalyst led the seed round and Floodgate led the pre-seed round.

Pavewise, a Bismarck, N.D.-based road construction technology company, raised $2.5 million in seed funding. C2 Ventures led the round and was joined by Connetic, Service Provider Capital, and others.

Private Equity

Chroma Color Corporation, backed by Arsenal Capital, acquired Ferco Color, a Chino, Calif.-based custom colorants manufacturer. Financial terms were not disclosed.

Southern Home Services, a portfolio company of Gryphon Investors, acquired Nick’s Plumbing & Air Conditioning, a Houston, Texas-based plumbing, heating, and air conditioning services company. Financial terms were not disclosed.

Exits

Mammoth Brands agreed to acquire Coterie, a New York City-based baby care brand, from American Pacific Group. Financial terms were not disclosed. 

MJH Life Sciences acquired BPD Healthcare, a Boca Raton, Fla.-based marketing services and communications firm for health care businesses, from WindRose Health Investors. Financial terms were not disclosed.



Source link

Continue Reading

Business

Leaders in Congress outperform rank-and-file lawmakers on stock trades by up to 47% a year

Published

on



Stocks held by members of Congress have been beating the S&P 500 lately, but there’s a subset of lawmakers who crush their peers: leadership.

According to a recent working paper for the National Bureau of Economic Research, congressional leaders outperform back benchers by up to 47% a year.

Shang-Jin Wei from Columbia University and Columbia Business School along with Yifan Zhou from Xi’an Jiaotong-Liverpool University looked at lawmakers who ascended to leadership posts, such as Speaker of the House as well as House and Senate floor leaders, whips, and conference/caucus chairs.

Between 1995 and 2021, there were 20 such leaders who made stock trades before and after rising to their posts. Wei and Zhou observed that lawmakers underperformed benchmarks before becoming leaders, then everything suddenly changed.

“Importantly, whilst we observe a huge improvement in leaders’ trading performance as they ascend to leadership roles, the matched ‘regular’ members’ stock trading performance does not improve much,” they wrote.

Leadership’s stock market edge stems in part from their ability to set the regulatory or legislation agenda, such as deciding if and when a particular bill will be put to a vote. Setting the agenda also gives leaders advanced knowledge of when certain actions will take place.

In fact, Wei and Zhou found that leaders demonstrate much better returns on stock trades that are made when their party controls their chamber.

In addition, being a leader also increases access to non-public information. The researchers said that while companies are reluctant to share such insider knowledge, they may prioritize revealing it to leaders over rank-and-file lawmakers.

Leaders earn higher returns on companies that contribute to their campaigns or are headquartered in their states, which Wei and Zhou said could be attributable to “privileged access to firm-specific information.”

The upper echelon also influences how other members of Congress vote, and the paper found that a leader’s party is much more likely to vote for bills that help firms whose stocks the leader held, or vote against bills that harmed them. And stocks owned by leadership tend to see increases in federal contract awards, especially sole-source contracts, over the following one to two years.

“These results suggest that congressional leaders may not only trade on privileged knowledge, but also shape policy outcomes to enrich themselves,” Wei and Zhou wrote.

Stock trades by congressional leaders are even predictive, forecasting higher occurrences of positive or negative corporate news over the following year, they added. In particular, stock sales predict the number of hearings and regulatory actions over the coming year, though purchases don’t.

Investors have long suspected that Washington has a special advantage on Wall Street. That’s given rise to more ETFs with political themes, including funds that track portfolios belonging to Democrats and Republicans in Congress.

And Paul Pelosi, former House Speaker Nancy Pelosi’s husband, even has a cult following among some investors who mimic his stock moves.

Congress has tried to crack down on members’ stock holdings. The STOCK Act of 2012 requires more timely disclosures, but some lawmakers want to ban trading completely.

A bipartisan group of House members is pushing legislation that would prohibit members of Congress, their spouses, dependent children, and trustees from trading individual stocks, commodities, or futures.

And this past week, a discharge petition was put forth that would force a vote in the House if it gets enough signatures.

“If leadership wants to put forward a bill that would actually do that and end the corruption, we’re all for it,” said Rep. Anna Paulina Luna, R-Fla., on social media on Tuesday. “But we’re tired of the partisan games. This is the most bipartisan bipartisan thing in U.S. history, and it’s time that the House of Representatives listens to the American people.”



Source link

Continue Reading

Business

Macron warns EU may hit China with tariffs over trade surplus

Published

on



French President Emmanuel Macron warned that the European Union may be forced to take “strong measures” against China, including potential tariffs, if Beijing fails to address its widening trade imbalance with the bloc.

“I’m trying to explain to the Chinese that their trade surplus isn’t sustainable because they’re killing their own clients, notably by importing hardly anything from us any more,” Macron told Les Echos newspaper in an interview published on Sunday.

“If they don’t react, in the coming months we Europeans will be obliged to take strong measures and decouple, like the US, like for example tariffs on Chinese products,” he said, adding that he had discussed the matter with European Commission President Ursula von der Leyen.

Macron has just returned from a three-day state visit in China, where he pressed for more investment as Paris seeks to recalibrate its relationship with the world’s second-largest economy. France’s goods trade deficit with China reached around €47 billion ($54.7 billion) last year, according to the French Treasury. Meanwhile, China’s goods trade surplus with the EU swelled to almost $143 billion in the first half of 2025, a record for any six-month period, according to data released by China earlier this year.

Tensions between France and China escalated last year after Paris backed the EU’s decision to impose tariffs on Chinese electric vehicles. Beijing retaliated by imposing minimum price requirements on French cognac, sparking fears among pork and dairy producers that they could be targeted next.

‘Life or Death’

Macron said the US approach to China was “inappropriate” and had worsened Europe’s position by diverting Chinese goods toward the EU market.

“Today, we’re stuck between the two, and it’s a question of life or death for European industry,” Macron said, while noting that Germany — Europe’s biggest economy — doesn’t entirely share France’s stance.

In addition to Europe needing to become more competitive, the European Central Bank too has a role to play in strengthening the EU’s single market, Macron said, arguing that monetary policy should take growth and jobs into account, not just inflation, he said.

He also said the ECB’s decision to continue selling the government bonds it holds risks pushing up long-term interest rates and weighing on economic activity.

“Europe must — and wants to — remain a zone of monetary stability and credible investment,” Macron said.



Source link

Continue Reading

Business

What bubble? Asset managers in risk-on mode stick with stocks

Published

on



There’s a time when investments run their course and the prudent move is to cash out. For global asset managers who’ve ridden double-digit gains in equities for three straight years, that time is not now.

“Our expectation of solid growth and easier monetary and fiscal policies supports a risk-on tilt in our multi-asset portfolios. We remain overweight stocks and credit,” said Sylvia Sheng, global multi-asset strategist at JPMorgan Asset Management.

“We are playing the powerful trends in place and are bullish through the end of next year,” said David Bianco, Americas chief investment officer at DWS. “For now we are not contrarians.”

“Start the year with sufficient exposure, even over-exposure to equities, predominantly in emerging market equities,” said Nannette Hechler-Fayd’herbe, EMEA chief investment officer at Lombard Odier. “We don’t expect a recession in 2026 to unfold.”

Those assessments came from Bloomberg News interviews with 39 investment managers across the US, Asia and Europe, including at BlackRock Inc., Allianz Global Investors, Goldman Sachs Group Inc. and Franklin Templeton.

More than three-quarters of the allocators were positioning portfolios for a risk-on environment through 2026. The thrust of the bet is that resilient global growth, further developments in artificial intelligence, accommodative monetary policy and fiscal stimulus will deliver outsize returns in all fashion of global equity markets. 

The call is not without risks, including simply its pervasiveness among the respondents, along with their overall high degree of assuredness. The view among the institutional investors also aligns with that of sell-side strategists around the globe. 

Should the bullishness play out as expected, it would deliver a stunning fourth straight year of bumper returns for the MSCI All-Country World Index. That would extend a run that’s added $42 trillion in market capitalization since the end of 2022 — the most value created for equity investors in history. 

That’s not to say the optimism is without merit. The artificial intelligence trade has added trillions in market value to dozens of firms plying the industry, but just three years after ChatGPT broke into the public consciousness, AI remains in the early phase of development.

No Tech Panic

The buy-side managers largely rejected the idea that the technology has blown a bubble in equity markets. While many acknowledged some pockets of froth in unprofitable tech names, 85% of managers said valuations among the Magnificent Seven and other AI heavyweights are not overly inflated. Fundamentals back the trade, they said, which marks the beginning of a new industrial cycle. 

“You can’t call it a bubble when you’re seeing tech companies deliver a massive earnings beat. In fact, earnings from the sector have outstripped all other US stocks,” said Anwiti Bahuguna, global co-chief investment officer at Northern Trust Asset Management.

As such, investors expect the US to remain the engine of the rally. 

“American exceptionalism is far from dead,” said Jose Rasco, chief investment officer at HSBC Americas. “As artificial intelligence continues to spread around the globe, the US will be a key participant.” 

Most investors echoed the sentiment expressed by Helen Jewell, international chief investment officer of fundamental equities at BlackRock, who suggested also searching outside the US for meaningful upside.

“The US is where the high-return high-growth companies are, so we have to be realistic about that. But those are already reflected in valuations, and there are probably more interesting opportunities outside the US,” she said.

International Boom

Profits matter above all else for equity investors, and huge bumps in government spending from Europe to Asia have stoked estimates for strong gains in earnings.

“We have begun to see a meaningful broadening of earnings momentum, both across market capitalizations and across regions, including Japan, Taiwan, and South Korea,” said Wellington Management equity strategist Andrew Heiskell. “Looking into 2026, we see clear potential for a revival of earnings growth in Europe and a wider range of emerging markets.”

India is one of the most compelling opportunities for 2026, according to Goldman Sachs Asset Management’s Alexandra Wilson-Elizondo, global co-head and co-chief investment officer of multi-asset solutions.

“We see real potential for India to become the Korea-like re-rating story of 2026, a market that transitions from tactical allocation to strategic core exposure in global portfolios,” she said. 

Nelson Yu, head of equities at AllianceBernstein, said he sees improvements outside of the US that will mandate allocations. He noted governance reform in Japan, capital discipline in Europe and recovering profitability in some emerging markets.

Small Cap Optimism

At the sector level, the investors are looking for AI proxies, notably among clean energy providers that can help meet the technology’s ravenous demand for power. Smaller stocks are also finding favor.

“The earnings outlook has brightened for small-capitalization stocks, industrials and financials,” said Stephen Dover, chief market strategist and head of Franklin Templeton Institute. “Small-cap stocks and industrials, which are typically more highly leveraged than the rest of the market, will see profitability rise as the Federal Reserve trims interest rates and debt servicing costs fall.”

Over at Santander Asset Management, Francisco Simón sees earnings growth of more than 20% for US small caps after years of underperformance. Reflecting the optimism, the Russell 2000 Index of such equities recently hit a record high.

Meanwhile, the combination of low valuations and strong fundamentals makes health care one of the most compelling contrarian opportunities in a bullish cycle, a preponderance of managers said.  

“Health-care related sectors can surprise to the upside in the US markets,” said Jim Caron, chief investment officer of cross-asset solutions at Morgan Stanley Investment Management. “This is a mid-term election year and policy may at the margin support many companies. Valuations are still attractive and have a lot of catch up to do.”

Virtually every allocator struck at least a note of caution about what lies ahead. The top worry among them was a rekindling of inflation in the US. If the Fed is forced by rising prices to abruptly pause or even end its easing cycle, the potential for turbulence is high.

“A scenario — which is not our base case — whereby US inflation rebounds in 2026 would constitute a double whammy for multi-asset funds as it would penalize both stocks and bonds. In this sense it would be much worse than an economic slowdown,” said Amélie Derambure, senior multi-asset portfolio manager at Amundi SA. 

“The way investors are headed for 2026, they need to have the Fed on their side,” she added.

Trade Caution

Another worry is around President Donald Trump’s capriciousness, particularly when it comes to trade. Any flareup in his trade spats that fuels inflation through heightened tariffs would weigh on risk assets. 

Oil and gas producers remain unloved by the group, though that could change if a major geopolitical event upends supply lines. While such an outcome would bolster those sectors, the overall impact would likely be negative for risk assets, they said.

“Any geopolitical situation that can affect the price of oil is what will have the largest impact on the financial markets. Clearly both the Middle East and the Ukraine/Russia situations can impact oil prices,” said Scott Wren, senior global market strategist at Wells Fargo Investment Institute.

Multiple respondents flagged European autos as a “no-go” area for 2026, citing intense competitive pressure from Chinese carmakers, margin compression and structural challenges in the transition to electric vehicles. 

“Personally I don’t believe for a minute that there will be a rebound in the sector,” said Isabelle de Gavoty at Allianz GI. 

Outside of those worries, most asset managers simply believe that there’s little reason to fret about the upward momentum being interrupted — outside, of course, from the contrarian signal such near-uniform bullishness sends.

“Everyone seems to be risk-on at the moment, and that worries me a bit in the sense that the concentration of positions creates less tolerance for adverse surprises,” said Amundi’s Derambure.  



Source link

Continue Reading

Trending

Copyright © Miami Select.